Biotest AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biotest AG with three other
companies in this sector in GERMANY :
Eckert & Ziegler Strahlen- und Medizinte
sales of 178.49 million Euro [US$208.03 million]
of which 59%
was Isotope Products),
(446.44 million Euro [US$520.32 million]
of which 76%
was EVT Execute), and
Dermapharm Holding SE
(700.88 million Euro [US$816.87 million]
of which 55%
was Pharmaceuticals and other products).
During the year ended December of 2019, sales at
Biotest AG were 419.10 million Euro (US$488.46 million).
increase of 4.7%
versus 2018, when the company's sales were 400.30 million Euro.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
18.5% in 2019, from
6.50 million Euro to 7.70 million Euro.
Biotest AG also saw significant increases in sales in
Therapy (up 6.7% to 371.90 million Euro)
Not all segments of Biotest AG experienced an increase in sales in 2019:
sales of Plasma and Services fell 12.8% to 39.50 million Euro.